Search results for: John R. Zalcberg

Items from 1 to 20 out of 27 results

article

Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot

Charles H. C. Pilgrim, Anna Maciejewska, Nadia Ayres, Sam Ellis, more

ANZ Journal of Surgery > 92 > 10 > 2565 - 2570

Background Non‐metastatic pancreatic ductal adenocarcinoma (PDAC) is classified as resectable (R), borderline resectable (BR) or locally advanced (LA). International Consensus Guidelines on these definitions exist, but have not been integrated into everyday Australian practice. The anatomical features on CT imaging lend themselves to synoptic reporting which should enhance completeness, comparability...

article

National clinical quality registry for pancreatic cancer – the time is nigh

Liane J. Ioannou, John R. Zalcberg, Daniel Croagh

ANZ Journal of Surgery > 92 > 7-8 > 1963 - 1963

article

Opportunities and barriers for the use of Australian cancer registries as platforms for randomized clinical trials

Mabel K. Yan, Nikki R. Adler, Natalie Heriot, Catherine Shang, more

Asia‐Pacific Journal of Clinical Oncology > 18 > 4 > 344 - 352

It is well recognized that randomized controlled trials (RCTs) are a powerful tool to investigate causal relationships, and are considered the gold standard level of research evidence. However, RCTs can be expensive and time‐consuming, and when they employ strict eligibility criteria, it results in an unrepresentative population and limited external validity. Recently, the registry‐based randomized...

article

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

Michael Moloney, David Faulkner, Emma Link, Danny Rischin, more

Cancer Chemotherapy and Pharmacology > 2018 > 82 > 5 > 865-876

Purpose 5-Fluorouracil (5FU) drug exposure correlates with treatment response and toxicity in cancer patients. Dosing is based upon body surface area which does not correlate with 5FU pharmacokinetics (PK)/pharmacodynamics. Therapeutic drug monitoring has enabled real-time 5FU dose adjustments: reducing toxicity with increased efficacy. The aim of this study was to assess feasibility of a 5FU monitoring...

article

Do all services provided as part of a clinical trial require research ethics and governance review?

Jeremy Kenner, John R. Zalcberg

Internal Medicine Journal > 47 > 10 > 1197 - 1199

Appropriate ethical oversight underpins the conduct of all clinical trials in Australia. In addition, clinical trials require a suitable approach to research governance in order to ensure that research is appropriately governed. However, such governance processes are often onerous and time‐consuming and are not required when trial practices are more appropriately understood as standard of care clinical...

article

3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer

Manfred P. Lutz, John R. Zalcberg, Michel Ducreux, Daniela Aust, more

European Journal of Cancer > 2017 > 79 > C > 41-49

The primary treatment of pancreatic cancer was the topic of the 3rd St. Gallen Conference 2016. A multidisciplinary panel reviewed the current evidence and discussed controversial issues in a moderated consensus session. Here we report on the key expert recommendations.It was generally accepted that radical surgical resection followed by adjuvant chemotherapy offers the only evidence-based treatment...

article

Corrigendum to “2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer” [Eur J Cancer 63 (August 2016) 11–24]

Manfred P. Lutz, John R. Zalcberg, Rob Glynne-Jones, Theo Ruers, more

European Journal of Cancer > 2016 > 68 > C > 208-209

article

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer

Manfred P. Lutz, John R. Zalcberg, Rob Glynne-Jones, Theo Ruers, more

European Journal of Cancer > 2016 > 63 > C > 11-24

Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic...

chapter

Gastrointestinal Stromal Tumors

John R. Zalcberg, Desmond Yip, Christine Hemmings, Bruce Mann, more

Gastrointestinal Oncology > 139-172

Gastrointestinal stromal tumors (GISTs) though relatively rare are the most common mesenchymal tumors of the gastrointestinal tract. In the past treatment was mainly confined to surgical resection. These tumors are relatively resistant to chemotherapy and radiotherapy. Recent understanding of pathogenesis especially the role of gain of function KIT gene mutations has enabled the rationale development...

chapter

Chemotherapy: Metastatic Disease

Kathryn M. Field, John R. Zalcberg

Current Clinical Oncology > Rectal Cancer > 189-222

Metastatic colorectal cancer is one of the most common malignancies in the Western world. Moreover, as this text so ably demonstrates, the optimal management of patients with rectal cancer at any stage of the disease truly requires a multidisciplinary effort that, depending on the stage of illness, can involve colorectal, hepatobiliary, and thoracic surgeons, pathologists, radiologists, radiation...

article

Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer

Kiley W.J. Loh, Michael Michael, John R. Zalcberg, Michael Jefford

Clinical Colorectal Cancer > 2015 > 14 > 3 > 192-197

Mismatch repair deficiency (dMMR) has been shown to confer a superior prognosis and is possibly predictive of a lack of benefit from fluoropyrimidine adjuvant chemotherapy (AC) for early-stage colon cancer (ESCC). We conducted a survey to assess medical oncologists' views regarding ESCC AC, with an emphasis on the use of MMR status to guide their recommendations.The survey was distributed to all members...

article

Accepting risk in the acceleration of drug development for rare cancers

David Ashley, David Thomas, Lia Gore, Rob Carter, more

The Lancet Oncology > 2015 > 16 > 4 > e190-e194

Rare cancers collectively contribute a disproportionate fraction of the total burden of cancer. The oncology community is increasingly facing small numbers of patients with each cancer subtype, requiring cooperation and collaboration to complete multicentre trials that advance knowledge and patient care. At the same time, new insights into the biology of rare cancers have led to an explosion in knowledge...

article

Gastric cancer: past progress and present challenges

Katrin M. Sjoquist, John R. Zalcberg

Gastric Cancer > 2015 > 18 > 2 > 205-209

This comment refers to the article available at: http://dx.doi.org/10.1007/s10120-014-0351-5 .

article

Bespoke treatment: Drivers beware!

Sharon Pattison, John R Zalcberg

Asia‐Pacific Journal of Clinical Oncology > 10 > 4 > 378 - 380

Significant progress has been made in the identification of molecular targets and targeted therapy is becoming a realistic option for patients with tumors for which potential driver mutations are identified. We present a case that highlights that the identification of a potential driver mutation does not confirm it as a key mutational event in every case and emphasizes the need for ongoing research...

article

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study

Hannah E. Carter, Diana Zannino, R. John Simes, Deborah J. Schofield, more

European Journal of Cancer > 2014 > 50 > 3 > 535-543

Based on the clinical data, bevacizumab has been approved in Australia and globally for the treatment of advanced colorectal cancer. However, limited evidence exists for its cost-effectiveness. The purpose of this study was to evaluate the cost effectiveness of adding bevacizumab to capecitabine monotherapy in patients with metastatic colorectal cancer, using data from the prospective economic evaluation...

article

Quality of life in patients with K‐RAS wild‐type colorectal cancer

Jolie Ringash, Heather‐Jane Au, Lillian L. Siu, Jeremy D. Shapiro, more

Cancer > 120 > 2 > 181 - 189

BACKGROUNDThe CO.20 trial randomized patients with K‐RAS wild‐type, chemotherapy‐refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo). METHODSQuality of life (QoL) was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 at baseline and at 2, 4, 6, 8, 12, 16,...

article

“A quiet still voice that just touches”: music’s relevance for adults living with life-threatening cancer diagnoses

Clare C. O’Callaghan, Fiona McDermott, Natasha Michael, Barbara A. Daveson, more

Supportive Care in Cancer > 2014 > 22 > 4 > 1037-1047

Purpose Music has historically aided health and loss-adaptation, however, cancer patients’ experience of music for self-care is not well understood. This study examines adult cancer patients’ views about music’s role before and after diagnosis. Methods Constructivist approach, with grounded theory informed design using convenience, snowball and theoretical sampling. Patients from Australian metropolitan...

article

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer

Manfred P. Lutz, John R. Zalcberg, Michel Ducreux, Jaffer A. Ajani, more

European Journal of Cancer > 2012 > 48 > 16 > 2941-2953

The 1st St. Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel clearly differentiated treatment and staging recommendations for the various gastroesophageal cancers. For locally advanced gastric cancer (⩾T3N+), the preferred treatment modality was pre- and postoperative chemotherapy. The majority of panel members would also treat T2N+ or even T2N0 tumours with a similar approach mainly...

article

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST

John R. ZALCBERG, Jayesh DESAI

Asia‐Pacific Journal of Clinical Oncology > 8 > 1 > 43 - 52

Tyrosine kinase inhibitors such as imatinib and sunitinib have greatly improved clinical outcomes for patients with gastrointestinal stromal tumors (GIST). Dose optimization of these agents is critical and involves multiple considerations, including ensuring a durable response, monitoring drug blood levels to confirm adequate dosing, deciding whether to use high‐dose imatinib or switch to second‐line...

article

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

Katrin M Sjoquist, Bryan H Burmeister, B Mark Smithers, John R Zalcberg, more

The Lancet Oncology > 2011 > 12 > 7 > 681-692

In a previous meta-analysis, we identified a survival benefit from neoadjuvant chemotherapy or chemoradiotherapy before surgery in patients with resectable oesophageal carcinoma. We updated this meta-analysis with results from new or updated randomised trials presented in the past 3 years. We also compared the benefits of preoperative neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy...

Publication date

Last 3 years (3)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: John R. Zalcberg

Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot

National clinical quality registry for pancreatic cancer – the time is nigh

Opportunities and barriers for the use of Australian cancer registries as platforms for randomized clinical trials

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

Do all services provided as part of a clinical trial require research ethics and governance review?

3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer

Corrigendum to “2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer” [Eur J Cancer 63 (August 2016) 11–24]

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer

Gastrointestinal Stromal Tumors

Chemotherapy: Metastatic Disease

Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer

Accepting risk in the acceleration of drug development for rare cancers

Gastric cancer: past progress and present challenges

Bespoke treatment: Drivers beware!

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study

Quality of life in patients with K‐RAS wild‐type colorectal cancer

“A quiet still voice that just touches”: music’s relevance for adults living with life-threatening cancer diagnoses

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

Filter options

Publication date

Content availability

Publication type

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: John R. Zalcberg

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options